Cited by 32Tuberculosis Research and EpidemiologyDiagnosis and treatment of tuberculosisInfectious Diseases and Tuberculosis

Tuberculosis Lymphadenitis in Ethiopia

Open access
Biadglegne, Fantahun, Tesfaye, Weghata, Anagaw, Belay, Tessema, Belay, Debebe, Tewodrose, Anagaw, Berhanu, Mulu, Andargachew, Sack, Ulrich +1 more·2013·Japanese Journal of Infectious Diseases

Abstract

Tuberculosis (TB) is one of the most serious public health challenges in Ethiopia. Indeed, Ethiopia ranks 7th among 22 countries with a high burden of TB worldwide. Both pulmonary TB and extrapulmonary TB (EPTB) are issues of concern. Ethiopia ranks 3rd in terms of the number of EPTB patients worldwide, with TB lymphadenitis (TBL) being the most common. According to the World Health Organization's Global TB Report 2009, the estimated number of TB patients in Ethiopia was 314,267 in 2007, with an estimated incidence rate of 378 patients per 100,000 population. Furthermore, 36% patients suffered from EPTB, with TBL accounting for 80% of these patients. In Ethiopia, pathological services, culture, and drug susceptibility testing for mycobacterium species are not available as routine tests, not even for cases with suspected infection by drug-resistant strains. Therefore, the management of multidrug-resistant (MDR) TB in Ethiopia is currently unsatisfactory. Against this background, a high index of clinical doubt and timely use of diagnostic methods, prompt confirmation of diagnosis, and early initiation of specific anti-TB treatment are the key factors for the successful management of MDR-TB and TBL in Ethiopia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7883/yoken.66.263

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Specificity of Xpert MTB/RIF against composite culture was in agreement with Biadigilegn et al (69.2%).

    “This is in agreement with the study done by Biadigilegn et al (specificity, 69.2%) [2].”

    From Diagnostic accuracy of Xpert MTB/RIF assay and non-molecular methods for the diagnosis of tuberculosis lymphadenitis (2019) · cites this paper as [2]

    The Diagnosis section discusses staining and culture but gives no Xpert MTB/RIF specificity estimate. Searches for “69.2% specificity” and “Xpert MTB/RIF” found no passage reporting the claimed comparison with composite culture. Page numbers were not available in our copy. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [14]14. Brainard, D. (2001): Scrofula in the 21st Century: an Update on Tuberculous Lymphadenitis. p. 1-6. Joint ID Conference.

Cited by

Sorted by citations

Authors
Biadglegne, F., Tesfaye, W., Anagaw, B., Tessema, B., Debebe, T., Anagaw, B., Mulu, A., Sack, U., & Rodloff, A. C.
Affiliations
  • University Hospital Leipzig (DE)
  • University of Gondar (ET)
  • Addis Ababa University (ET)
  • Faculty of Medicine and Health Sciences, Bahir Dar University
Venue
Japanese Journal of Infectious Diseases
Published
2013
Volume
66
Issue
4
Pages
263-268
ISSN
  • 1344-6304 (ISSN-L)
  • 1884-2836
OpenAlex
W2007724496
Cited by
32
References
40
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 4 · 2015: 4 · 2014: 3
FWCI
0.47
Type
journal article
Language
en
Open access
Locations
  • Japanese Journal of Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion)
  • Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
Funders
  • Deutscher Akademischer Austauschdienst
  • Fraunhofer-Institut für Zelltherapie und Immunologie
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Surgery › Diagnosis and treatment of tuberculosis
  • Health Sciences › Medicine › Surgery › Infectious Diseases and Tuberculosis
Keywords
tuberculous lymphadenitis, extrapulmonary tuberculosis, multidrug-resistant tuberculosis, Ethiopia, tuberculosis incidence, tuberculosis diagnosis, drug susceptibility testing, tuberculosis treatment
MeSH terms
Ethiopia, Humans, Tuberculosis, Lymph Node, Incidence, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review